TW202132346A - 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 - Google Patents

使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 Download PDF

Info

Publication number
TW202132346A
TW202132346A TW109140405A TW109140405A TW202132346A TW 202132346 A TW202132346 A TW 202132346A TW 109140405 A TW109140405 A TW 109140405A TW 109140405 A TW109140405 A TW 109140405A TW 202132346 A TW202132346 A TW 202132346A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
TW109140405A
Other languages
English (en)
Chinese (zh)
Inventor
克莉絲汀 莫瑞兒 寇可利
強納森 安卓 克路福特
威廉 湯姆士 三世 夕孟德斯
Original Assignee
瑞士商依牧諾萬科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商依牧諾萬科學有限公司 filed Critical 瑞士商依牧諾萬科學有限公司
Publication of TW202132346A publication Critical patent/TW202132346A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109140405A 2019-11-19 2020-11-18 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 TW202132346A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19

Publications (1)

Publication Number Publication Date
TW202132346A true TW202132346A (zh) 2021-09-01

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109140405A TW202132346A (zh) 2019-11-19 2020-11-18 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法

Country Status (11)

Country Link
US (1) US20230049011A1 (https=)
EP (1) EP4061486A1 (https=)
JP (1) JP7722991B2 (https=)
KR (1) KR20220100880A (https=)
CN (1) CN114728180A (https=)
AU (1) AU2020387399A1 (https=)
CA (1) CA3157797A1 (https=)
IL (1) IL292889A (https=)
MX (1) MX2022005862A (https=)
TW (1) TW202132346A (https=)
WO (1) WO2021101975A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
US20260078188A1 (en) * 2022-09-06 2026-03-19 Immunovant Sciences Gmbh Methods of treating graves’ disease using anti-fcrn antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3137504T3 (fi) 2014-04-30 2023-08-07 Hanall Biopharma Co Ltd Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
CA3032415A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Also Published As

Publication number Publication date
IL292889A (en) 2022-07-01
JP7722991B2 (ja) 2025-08-13
US20230049011A1 (en) 2023-02-16
EP4061486A1 (en) 2022-09-28
CN114728180A (zh) 2022-07-08
WO2021101975A1 (en) 2021-05-27
JP2023502398A (ja) 2023-01-24
AU2020387399A1 (en) 2022-05-19
MX2022005862A (es) 2022-06-23
CA3157797A1 (en) 2021-05-27
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
TWI859164B (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
US20230235063A1 (en) Antibody binding to fcrn for treating autoimmune diseases
JP2026063214A (ja) 高濃度抗ｃ５抗体製剤
TW202136314A (zh) 抗ｃｃｒ８抗體及其用途
EP2377553A1 (en) Use of IL-1 antibodies for treating ophthalmic disorders
CA2447139A1 (en) Specific binding proteins and uses thereof
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
TW202132346A (zh) 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法
US20260078188A1 (en) Methods of treating graves’ disease using anti-fcrn antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
HK40058301B (zh) 使用抗fcrn抗体治疗格雷夫斯眼病的方法
TW202417512A (zh) 含有抗tigit抗體的配製物及其使用方法
HK40058301A (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
TWI623324B (zh) 用於治療自體免疫病的與fcrn結合的抗體
HK40124168A (zh) 使用抗fcrn抗体治疗格雷夫斯病的方法
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료